Company Overview
About Scipher Medicine
Scipher Medicine is a precision immunology company headquartered in Waltham, Massachusetts, applying AI and network biology to solve one of medicine's most persistent problems: predicting which therapy a patient with an autoimmune disease will actually respond to. The company's core platform integrates protein-protein interaction mapping, RNA sequencing data from the largest non-oncology clinico-transcriptomic biobank, and machine learning to identify molecular signatures that distinguish patients likely to respond from those likely to fail a given therapy.
Business Model & Competitive Advantage
Scipher's flagship product, PrismRA, is the first molecular test in immunology to receive clinical validation for predicting patient response to TNF inhibitor drugs in rheumatoid arthritis. Built on a 23-feature molecular signature (19 transcriptomic, three clinical, one blood biomarker), PrismRA enables rheumatologists to make more informed treatment decisions at the point of prescription — reducing the months or years patients spend on ineffective therapies before finding one that works. The company has raised $110M in total funding across six rounds, with its latest financing round led by Cowen Healthcare Investments, and announced a strategic partnership with InnoSIGN in April 2025 to expand into additional immune-mediated disease indications.
Competitive Landscape 2025–2026
Scipher Medicine's broader vision extends beyond rheumatoid arthritis to other autoimmune conditions and eventually into cardiovascular and central nervous system diseases where similar molecular stratification approaches could improve outcomes. The company sits at the intersection of diagnostics, digital health, and pharmaceutical services, positioning PrismRA as both a standalone clinical test and a platform for precision medicine partnerships with biopharmaceutical companies developing next-generation immunology therapeutics.
Key Differentiators
Emerging Innovator
Scipher Medicine is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Scipher Medicine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Scipher Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Scipher Medicine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Scipher Medicine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →